Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
揭开爵士制药的神秘面纱：来自15条分析师评论的见解
In the preceding three months, 15 analysts have released ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有15位分析师发布了Jazz Pharmicals（纳斯达克股票代码：JAZZ）的评级，提出了从看涨到看跌的各种观点。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $195.73, a high estimate of $230.00, and a low estimate of $131.00. Marking an increase of 1.35%, the current average surpasses the previous average price target of $193.12.
分析师通过对12个月目标股价的评估提供了更深入的见解，显示平均目标价为195.73美元，最高估计为230.00美元，低估值为131.00美元。当前的平均价格上涨了1.35％，超过了之前的平均目标股价193.12美元。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级：详细明细
A clear picture of Jazz...
通过对分析...
登录免费看全文
登录/注册